1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid

We are 1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid CAS:112811-72-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
CAS.NO: 112811-72-0
Synonyms:
1-Cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Gatifloxacin Carboxyclic Acid

Molecular Formula:C14H11F2NO4
Molecular Weight:295.23800

Physical and Chemical Properties:
Density: 1.174g / cm3
Boiling point: 245.2ºC at 760 mmHg
Melting point: 192-194ºC
Flash point: 102.1ºC
Refractive index: 1.629

Specification:
Appearance: White or off-white crystalline powder
Purity:≥99%
Assay:  ≥98.5% 
Impurity: ≤0.5% 
Relative matter: ≤1.5% 
Loss on dry:  ≤0.5% 
Residue on ignition:  ≤0.2%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Moxifloxacin hydrochloride CAS:186826-86-8
Intermediates of Moxifloxacin CAS:151096-09-2

Related News: Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed.Tetraethyl orthosilicate hydrolyzed China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition.1-methoxy-3-nitro-5-(trifluoromethyl)benzene CAS:328-79-0 The company has now selected a single engineered iPSC clone, and generated and fully-characterized the master engineered iPSC bank for GMP production of FT819.5-Amino-2,3-dihydrobenzofuran CAS:42933-43-7 Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.Established pharmaceutical companies have abandoned the original model of the entire industry chain, stripped R & D and production links through outsourcing, and shifted their focus to product layout and global operations.